Mesoblast Limited (ASX: MSB) announced a US$50 million of financing from NovaQuest Capital Management, L.L.C. for continuous development and commercialization of its allogeneic product candidate remestemcel-L (MSC-100-IV) for children with steroid refractory acute Graft versus Host Disease (aGVHD). NovaQuest will provide support to its plans to bring remestemcel-L to market and this transaction will be underpinned by the strength of its GVHD Phase 3 clinical trial result. This trial is currently being managed in partnership with IQVIA, the clinical research organization that provides trial oversight and global development experience.
Further, it is expected that NovaQuest will provide a non-dilutive US$40 million, eight-year term loan and purchase US$10 million of Mesoblast common shares and this per share equity purchase price will represent a 5 per cent premium to the 10-day volume weighted average price at the time of execution of the equity purchase agreement. Consequently, Mesoblast will issue the shares and will draw the first tranche of the loan for the amount of US$30 million on closing and in addition US$10 million will be drawn on marketing approval of remestemcel-L by the United States Food and Drug Administration (FDA).
It was recorded that Mesoblast’s open-label Phase 3 trial enrolled 55 children with steroid-refractory aGVHD (aged between two months and 17 years) in 32 sites across the United States and 89 per cent of patients were suffering from the most severe form, grade C/D aGVHD. Moreover, NovaQuest has been providing novel solutions to the biopharmaceutical industry and helped in funding for the development and commercialization of strategic assets for two decades that reduced the cost of care and helped in meeting the unmet medical needs that improved the quality of life of patients. After this announcement, the stock price moved up by 3.72 per cent and was trading at $1.535 (as on 2 July 2018 1:25 PM AEST).
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.